Shawn Alaron Abeynaike

Mr. Shawn Alaron Abeynaike

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
THTridu Huynh
Tridu Huynh
AMAbeera Mehmood
Abeera Mehmood
TKTeha Kim
Teha Kim
KFKayla Frank
Kayla Frank
SPSilke Paust
Silke Paust
Mice reconstituted with human immune systems are instrumental in the investigation of HIV-1 pathogenesis and therapeutics. Natural killer (NK) cells have long been recognized as a key mediator of innate anti-HIV responses. However, established humanized mouse models do not support robust human NK cell development from engrafted human hematopoietic stem cells (HSCs). A major obstacle to human NK cell reconstitution is the lack of human interleukin-15 (IL-15) signaling, as murine IL-15 is a poor stimulator of the human IL-15 receptor. Here, we demonstrate that immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice expressing a transgene encoding human IL-15 (NSG-Tg(IL-15)) have physiological levels of human IL-15 and support long-term engraftment of human NK cells when transplanted with human umbilical-cord-blood-derived HSCs. These Hu-NSG-Tg(IL-15) mice demonstrate robust and long-term reconstitution with human immune cells, but do not develop graft-versus-host disease (GVHD), allowing for long-term studies of human NK cells. Finally, we show that these HSC engrafted mice can sustain HIV-1 infection, resulting in human NK cell responses in HIV-infected mice. We conclude that Hu-NSG-Tg(IL-15) mice are a robust novel model to study NK cell responses to HIV-1.

8 July 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DLDuy Tri Le
Duy Tri Le
THTridu Huynh
Tridu Huynh
BBBryan Burt
Bryan Burt
GIGeorge Van Buren, II
George Van Buren, II
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
SPSilke Paust
Silke Paust
Existing patient-derived xenograft (PDX) mouse models of solid tumors lack a fully tumor donor–matched, syngeneic, and functional immune system. We developed a model that overcomes these limitations by engrafting lymphopenic recipient mice with a fresh, undisrupted piece of solid tumor, whereby tumor-infiltrating lymphocytes (TILs) persisted in the recipient mice for several weeks. Successful tumor engraftment was achieved in 83% to 89% of TIL-PDX mice, and these were seen to harbor exhausted immuno-effector as well as functional immunoregulatory cells persisting for at least 6 months postengraftment. Combined treatment with interleukin-15 stimulation and immune checkpoint inhibition resulted in complete or partial tumor response in this model. Further, depletion of cytotoxic T lymphocytes and/or natural killer cells before combined immunotherapy revealed that both cell types were required for maximal tumor regression. Our TIL-PDX model provides a valuable resource for powerful mechanistic and therapeutic studies in solid tumors.

26 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDuy Tri Le
Duy Tri Le
BBBryan M. Burt
Bryan M. Burt
GIGeorge Van Buren, II
George Van Buren, II
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
CZCristina Zalfa
Cristina Zalfa
SPSilke Paust
Silke Paust
Existing patient-derived-xenograft (PDX) mouse models of solid tumors lack a fully tumor-donor matched “syngeneic” and functional immune system. We developed such a model by engrafting lymphopenic recipient mice with a fresh undisrupted piece of solid tumor, whereby tumor-infiltrating lymphocytes (TIL) expanded in the recipient mice for several weeks. Tumors engrafted in about seventy to eighty percent of s yngeneic- i mmune- s ystem-PDX (SIS-PDX) mice, which harbored tumor-exhausted immune-effector and functional immune-regulatory cells persisting for at least six-months post-engraftment. Interleukin-15 (IL-15)-stimulation in addition to immune checkpoint inhibition (ICI), prevented resistance, resulting in complete or partial response to combined treatment. Further, the depletion of Cytotoxic T lymphocytes (CTLs) and/or Natural Killer (NK) cells from combined immunotherapy in SIS-PDX mice revealed that both cell types are required for the maximal response to tumor. Our novel SIS-PDX model provides a valuable resource for powerful mechanistic and therapeutic studies designed to eradicate solid tumors.

6 December 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
SPSilke Paust
Silke Paust
Corrigendum: Humanized Mice for the Evaluation of Novel HIV-1 Therapies

3 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KFKayla Frank
Kayla Frank
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
RNRana Nikzad
Rana Nikzad
RPReesha R. Patel
Reesha R. Patel
ARAmanda Roberts
Amanda Roberts
SPSilke Paust
Silke Paust
Alcohol use disorder (AUD) is a chronic relapsing disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. AUD is associated with a variety of physiological changes and is a substantial risk factor for numerous diseases. We aimed to characterize systemic alterations in immune responses using a mouse model of chronic intermittent alcohol exposure to induce alcohol dependence. We exposed mice to chronic intermittent ethanol vapor for 4 weeks and used multiparametric flow cytometry to analyze the expression of cytokines IFN-γ, IL-4, IL-10, IL-12 and IL-17 by different immune cells in the blood, spleen and liver of alcohol dependent and non-dependent control mice. We found increases in IFN-γ and IL-17 expression in a cell type- and organ-specific manner. Often, B cells and neutrophils are primary contributors to increased IFN-γ and IL-17 levels while other cell types play a secondary role. We conclude that chronic alcohol exposure promotes systemic pro-inflammatory IFN-γ and IL-17 responses in mice. These responses are likely important in the development of alcohol-related diseases, but further characterization is necessary to understand the initiation and effects of systemic inflammatory responses to chronic alcohol exposure.

1 July 2026 in JCO Oncology Advances
Verified
Journal Article
Open access
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
RARoberta Vezza Alexander
Roberta Vezza Alexander
CSChristina A. Snider
Christina A. Snider
IPIn Hwan Park
In Hwan Park
SKShumei Kato
Shumei Kato
GBGregory P Botta
Gregory P Botta